Annexon, Inc. (ANNX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$4.87+0.62%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · ANNX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
ANNX — earnings miss
Dated 2026-08-12
of this Current Report on Form 8-K, including Exhibit 99.1, shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as expressly set forth by specific reference in such a filing.
Why it matters: Positive data could support the development of a new treatment for autoimmune diseases. It is an important part of the pipeline.
Supportive ifThe company shares strong proof-of-concept data. This is for ANX1502 in treating cold agglutinin disease.
Worry ifThe company shares bad data or delays in the proof-of-concept trial.
Why it matters: Funding is important for Annexon to keep operating in the second half of 2027.
Supportive ifA new funding announcement or partnerships to cover costs.
Worry ifNo news on funding and losses continue.
Why it matters: Updates on finances can affect how investors feel and how plans are made.
Worry ifManagement says cash will last until 2028 without big changes.
Less concerning ifGuidance shows a shorter cash runway or more financial pressure.
Why it matters: Hitting these milestones is key for Annexon's future and funding plans.
Supportive ifA key milestone in the late-stage program is achieved.
Worry ifThe timeline or criteria for milestones is not met.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$242 on $10,000 · ±2.4% | How much price usually moves either way. |
| Bad day | $693 loss on $10,000 · 6.9% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,506 loss on $10,000 · 35.1% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Good POC data could prove ANX1502 works as a treatment for autoimmune diseases. This would help future work.
Supportive ifPositive POC data shows effective PK/PD results in patients.
Worry ifPOC data shows no big worries about how well it works or safety.
Why it matters: If healthcare sector growth speeds up, it may benefit Annexon. This could improve investor confidence.
Supportive ifHealthcare sector revenue growth rises above 10% year over year.
Worry ifHealthcare sector revenue growth remains below 10% year over year.
Why it matters: Hitting these milestones is key for funding and future growth. It shows the product's potential.
Supportive ifA public announcement will share news about a key goal in the late-stage program.
Worry ifDelay or failure to meet a key milestone in the late-stage program.
Why it matters: Good data could change treatment for geographic atrophy. This is important for the company's growth.
Supportive ifData from the ARCHER II Phase 3 trial shows strong vision preservation.
Worry ifData from the ARCHER II trial fails to meet primary endpoints.
Why it matters: Earnings results can show financial health and operational progress. They can affect stock sentiment.
Watch forQ2 earnings were better than expected. This shows strong performance.
Also watch forQ2 earnings did not meet expectations. This may mean problems in operations.
Why it matters: Updates on cash runway will indicate if Annexon can fund its operations through 2027. This affects investor confidence.
Watch forCash runway extends into the second half of 2027.
Also watch forCash runway is getting shorter, which means funding may be a problem.
Why it matters: Results will show how well tanruprubart works. They are key for the company's trust.
Watch forGood updates from the FORWARD study show clear benefits for different patient groups.
Also watch forBad news from the FORWARD study shows no real improvement or safety problems.
Why it matters: This submission is key for gaining approval for a new GBS treatment. It could address a major unmet need in a serious condition.
Supportive ifThe company submits the Biologics License Application (BLA) to the FDA by the end of Q4 2026.
Worry ifThe BLA submission is delayed beyond Q4 2026 or not submitted at all.
Why it matters: This data will show if vonaprument can keep vision in GA patients. Good results may help investors feel more confident.
Supportive ifThe company shares good Month 15 results from the ARCHER II trial.
Worry ifThe Month 15 results are negative or unclear.
Why it matters: This update will provide insights into a new treatment for autoimmune diseases. Positive data could enhance the pipeline's value.
Supportive ifThe company shares positive data from the trial for ANX1502.
Worry ifThe update shows no significant findings or negative results from the trial.